[ad_1]
(Envato)
SAO PAULO – A study on the treatment against the new coronavirus published on Thursday night (16) has encouraged investors from yesterday’s market. This Friday, the US stock indices are up more than 2%.
The University of Chicago medical school hospital said treatment with the drug Remdesivir, produced by Gilead Sciences, was showing rapid results in 113 critically ill patients.
In total, 125 people infected with the new coronavirus participated in the program, which is currently in phase 3, according to information published by the health website Stat News, which obtained the data. Two of them died.
Last week, the New England Journal of Medicine published an analysis indicating that the majority of Covid-19 patients treated with the same drug show clinical improvement.
Remdesivir was one of the first drugs identified as candidates for the treatment of Covid-19, as it has shown promise in the past in the treatment of SARS and MERS, both caused by coronaviruses.
Despite the enthusiasm these studies have brought to the market, scientists and analysts say caution is needed.
Gilead herself said in a statement to Reuters that “all data must be analyzed to draw conclusions.” The University of Chicago stated that “drawing conclusions at this time is premature and scientifically unhealthy.”
Biotech stocks analysts at JPMorgan wrote that the research released Thursday “appears to represent another encouraging, albeit largely anecdotal, stimulus given for this potential drug candidate.”
Meanwhile, Barclays’ health sector analysis team called the drug report “encouraging,” but emphasized that many questions remain.
The biggest problem is that the study still needs more control and was done by only one group. It was based on information that is still being analyzed and published by a website, Stat News, that is not related to Gilead.
Barclays analysts said “while these data are encouraging, they are uncontrolled and come from a single source.” Meanwhile, Jefferies analysts also recalled that these tests didn’t even have a control group that used placebos.
“There are still a lot of things that we don’t know and therefore we hesitate to put a lot of courage into the results generated in a single center without a control group,” said JPMorgan. “Fortunately, we won’t have to wait long for the Phase 3 reading in critically ill patients.”
Gilead expects his test results on patients with severe Covid-19 to be released later this month. Data from his trials on patients with moderate symptoms are expected in May.
In addition to these Gilead studies, there are several others underway to evaluate Remdesivir, including one in phase two from the United States National Institute of Health, which is a randomized, placebo-controlled, adaptive study.
How to become a constant trader? Learn in a free course the configurations of Giba, XP technical analyst, to trade on the Stock Market!
[ad_2]
